A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Portfolio News / By Karina Tin November 2, 2023 A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More »
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights Portfolio News / By Karina Tin November 2, 2023 NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights Read More »
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Portfolio News / By Karina Tin November 1, 2023 Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Read More »
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Karina Tin October 26, 2023 Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference Portfolio News / By Karina Tin October 23, 2023 Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference Read More »
ORIC-114’s Initial Phase 1 Dose Escalation Data in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile Portfolio News / By Karina Tin October 21, 2023 ORIC-114’s Initial Phase 1 Dose Escalation Data in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile Read More »
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy Portfolio News / By Karina Tin October 19, 2023 Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy Read More »
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® Portfolio News / By Karina Tin October 15, 2023 Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin October 12, 2023 Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Spontaneous Urticaria Portfolio News / By Karina Tin October 12, 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Spontaneous Urticaria Read More »
